Swiss Insurance Stock News

Chocoladefabriken Lindt & Sprüngli (SWX:LISN) has drawn fresh attention after releasing full year 2025 results, showing higher sales, revenue and net income, and announcing an annual dividend of CHF 1,800 per share. See our latest analysis for Chocoladefabriken Lindt & Sprüngli. At a share price of CHF 112,800, Chocoladefabriken Lindt & Sprüngli has seen a 7 day share price return of 0.71%, while the 30 day share price return of an 8.14% decline contrasts with a 5 year total shareholder...

On 12 March 2026, Swiss Life Holding AG reported full-year 2025 results showing net income of CHF 1,234 million and slightly higher earnings per share, while also announcing an annual dividend of CHF 36.50 per share payable on 13 May 2026. The combination of steady profit growth and a higher cash distribution offers fresh insight into how Swiss Life balances shareholder returns with capital needs. With Swiss Life pairing higher earnings per share and an increased CHF 36.50 dividend, we’ll...

Julius Bär Gruppe (SWX:BAER) has posted its FY 2025 results with second half revenue of CHF 1,950.2 million and basic EPS of CHF 2.28, while trailing twelve month revenue came in at CHF 3,760.4 million and EPS at CHF 3.72. Over recent periods the bank has seen revenue move from CHF 1,916.3 million in the second half of 2024 to CHF 1,810.2 million in the first half of 2025 and then to CHF 1,950.2 million in the latest half, alongside EPS shifting from CHF 2.78 to CHF 1.44 and then CHF 2.28...

If you are wondering whether Alcon's current share price reflects its true worth, this article walks through the key numbers that matter for you as an investor. Alcon recently closed at $61.16, with returns of a 2.5% decline over 7 days, 0.3% over 30 days, a 3.7% decline year to date and a 22.2% decline over the past year, which raises questions about how the market is currently pricing the stock. Recent coverage around Alcon has focused on its position in the medical equipment space and how...

Wondering whether Nestlé at around CHF 80.61 is a bargain, fairly priced, or expensive? This article walks through the key clues behind the current share price. The stock has returned 0.7% over the last 7 days, 1.3% over the last 30 days, 5.5% year to date, but is still showing a 7.5% decline over 1 year, an 18.8% decline over 3 years and a 9.7% decline over 5 years. Recent headlines around Nestlé have focused on the business as a core global consumer staple, with ongoing attention on how it...

If you are wondering whether Partners Group Holding is attractively priced today, you are not alone. Many investors are trying to work out if the current share price reflects its long term potential. The stock closed at CHF 811.60, with returns of 1% decline over the last 7 days, 14.7% decline over 30 days, 21.2% decline year to date, and 35.9% decline over 1 year, while the 3 year return stands at 21.3% and the 5 year return at 15.6% decline. These moves have played out against a steady...

Earlier this month, ALSO Holding AG’s Board of Directors approved a share repurchase program of up to 9.74% of its capital for €120 million, aiming to use the treasury shares for acquisitions, liquidity, and long‑term management incentives. Around the same time, the company launched an AI Competence Center to help its partner network sell AI solutions, underscoring its focus on Microsoft 365 Copilot and the broader European AI ecosystem. We will now examine how the launch of the AI...

Amrize (SWX:AMRZ) is drawing fresh attention after launching its EVERtect high performance concrete range at CONEXPO CON/AGG, pairing this product rollout with recent insider and institutional share purchases. See our latest analysis for Amrize. Despite the EVERtect launch, insider buying and the upcoming AGM, Amrize’s recent momentum has been soft, with a 30-day share price return of a 4.62% decline and a year-to-date share price return of a 2.20% decline from CHF43.52. If this concrete...

If you are wondering whether Cosmo Pharmaceuticals at around CHF 87.00 is still offering value after a solid run, this article walks through what the current price might be implying about the company. The stock has pulled back recently, with a 19.0% decline over the last 7 days and a 24.6% decline over the last 30 days, even though the 1 year return sits at 66.3% and the 3 year return at 70.4%. These moves come against a backdrop where investors are reassessing prior gains and weighing Cosmo...

In early March 2026, Giatec Scientific announced a commercial partnership with Sika to integrate Giatec’s AI-powered concrete sensors, software, and data tools into Sika’s global concrete product offering, supporting the Fast Forward program that targets an incremental EBITDA contribution of CHF 150.00 to 200.00 million by 2028. This move expands Sika’s digital capabilities across the concrete value chain, giving its customers access to real-time, AI-driven mix optimization and monitoring...

Novartis (SWX:NOVN) is back on investor radars after recent share price moves, with the stock showing mixed short term performance but stronger returns over the past 3 months and year. See our latest analysis for Novartis. The recent 1 week and 1 day share price declines sit against a stronger 90 day share price return of 14.5% and a 1 year total shareholder return of 28.5%. This suggests momentum has been building over a longer horizon despite near term softness. If Novartis has caught your...

Partners Group Holding (SWX:PGHN) opened FY 2025 with first half revenue of CHF 1.2b and basic EPS of CHF 22.24, setting the tone for another data rich year of results. The company has seen revenue move from CHF 964.3m in the first half of 2024 to CHF 1.15b in the second half of 2024 and then to CHF 1.16b in the first half of 2025, while basic EPS shifted from CHF 19.52 to CHF 23.89 and then to CHF 22.24 over the same periods. With trailing net profit margins described at 49.2% compared with...

Sika (SWX:SIKA) has drawn fresh attention after announcing a commercial partnership with Giatec Scientific to integrate AI driven concrete sensors and software into its global product range for producers worldwide. See our latest analysis for Sika. That partnership news lands against a tougher backdrop, with Sika’s share price at CHF140.9 and a 30 day share price return showing a 9.68% decline, while the 1 year total shareholder return of 37.07% decline points to pressure that predates this...

SIG Group (SWX:SIGN) is back in focus after its latest full year results showed sales of €3,248.7 million and a shift from €194.5 million net income to a €87 million net loss. See our latest analysis for SIG Group. The earnings release has come after a mixed stretch for the stock, with a 90 day share price return of 25.65% and a 1 year total shareholder return decline of 31.77%. This suggests recent momentum has improved while longer term returns remain weak as investors reassess the risk...

Earnings and Dividend Decisions Put Kuehne + Nagel International in Focus Kuehne + Nagel International (SWX:KNIN) is back on investors’ radar after reporting full year 2025 results that included lower sales, softer earnings and a reduced annual dividend per share. See our latest analysis for Kuehne + Nagel International. The earnings miss and lower dividend appear to have weighed on sentiment, with the share price at CHF172.15 and a 1 year total shareholder return of 14.5% decline, while the...

If you have been wondering whether Roche Holding shares are now offering good value or pricing in a lot of optimism, you are not alone. The stock last closed at CHF 332.40, with a 7 day return of an 8.4% decline, a 30 day return of a 6.7% decline, a 1 year return of 11.7% and a 3 year return of 40.4%. Recent moves in the share price sit against ongoing attention on Roche Holding as a major healthcare group, including continuing focus on its pharmaceuticals and diagnostics businesses and...

Cosmo Pharmaceuticals (SWX:COPN) has kicked off FY 2025 with first half revenue of €51.7 million and a basic EPS loss of €0.13, following FY 2024 second half revenue of €130.6 million with basic EPS of €3.45 and first half 2024 revenue of €136.2 million with basic EPS of €4.42. Over the trailing twelve months in the data, revenue is €182.3 million with basic EPS of €3.68. Investors may focus on how the latest dip into a small loss fits against a period where margins and earnings have...

Why the Bichsel decision matters for Galenica shareholders Galenica (SWX:GALE) has launched a consultation process on a planned production closure at its Bichsel subsidiary, a move that could affect up to 170 jobs by the end of 2026. The company plans to support affected employees with financial assistance, career guidance, and potential alternative roles within the wider Galenica network. A final decision is expected after the consultation concludes in mid March 2026. See our latest analysis...

Why Zurich Insurance Group (SWX:ZURN) is back on investors’ radar Zurich Insurance Group (SWX:ZURN) has drawn fresh attention after reporting its highest-ever annual profit for 2025, supported by its U.S. Farmers Management Services business and a benign catastrophe year. The board has also proposed lifting the dividend to CHF 30 per share, a 7% increase, subject to shareholder approval, giving investors a fresh data point to reassess the stock. See our latest analysis for Zurich Insurance...

Amrize (SWX:AMRZ) has introduced its new EVERtect™ high-performance concrete range for customers in North America. The portfolio includes multiple specialized mixes tailored for different construction uses across the U.S. and Canada. The launch expands Amrize’s presence in high-spec concrete solutions for both structural and low-carbon applications. For you as an investor, this move highlights how Amrize is positioning its core materials business around more differentiated, higher-spec...

If you are wondering whether ABB's current share price still makes sense after a strong run, this article breaks down what you are really paying for the business today. ABB shares last closed at CHF 67.20, with returns of 46.1% over 1 year and 181.5% over 5 years. The shorter term picture is mixed, with a 4.8% decline over 7 days but a 9.7% gain year to date. Recent headlines have focused on ABB's ongoing position as a major player in electrification and automation, as well as its exposure...

Alcon reports that more than 175 million of its intraocular lenses have been implanted worldwide. The milestone highlights broad adoption of the company’s presbyopia-correcting IOLs across global eye care practices. Alcon plans further intraocular lens launches, subject to regulatory approvals. For investors following Alcon (SWX:ALC), this update comes with the shares trading at CHF63.96 and a value score of 4. The stock shows a 22.3% decline over the past year, while 3-year and 5-year...

On 24 February 2026, Iconovo AB announced it had signed a Letter of Intent with Lonza Group to pursue a long-term collaboration around spray dried formulation capabilities for inhalable biologics, building on their existing work on an obesity project. This potential alliance links Lonza’s CDMO scale with Iconovo’s five-platform inhaler technology targeting biologics and high-value respiratory franchises with global turnover of about US$9.00 billion. We’ll now examine how this focus on spray...

Avolta AG recently completed the cancellation of about 4.9 million treasury shares, reducing its registered share capital to CHF 708,241,695 across 141,648,339 shares, while continuing to expand its food and beverage footprint at key airports in Italy and Canada. This combination of a tighter share base and integrated travel retail and dining growth highlights Avolta’s focus on capital efficiency alongside strengthening its airport partner relationships. Next, we’ll examine how Avolta’s...